Author: Jennifer Levy

An LGMD by any other name … is still an LGMD: New nomenclature for the LGMDs

Those who recently attended the National LGMD Conference in Chicago learned that the LGMDs are getting new names. In the old naming system, dominant LGMDs were called LGMD1s and recessive LGMDs were called LGMD2s. The subtypes were further delineated

New resource to learn about clinical research opportunities for LGMD2A

Are you or a family member with LGMD2A interested in participating in clinical research studies or trials? Click here to view C3’s new Clinical Research Opportunity Resource Center to learn more about clinical research and current opportunities to participate. This

University of Florida College of Medicine Study Recruiting LGMD2A Patients Living in the Southeast U.S. and Texas

Individuals with LGMD2A, a form of calpainopathy, are being sought for a Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) study. Please direct any questions related to this study, including participation guidelines and aims, to Dr. Glenn Walter, University of Florida

Published Research Alert: Gene Correction of LGMD2A Specific iPSCs for the Development of Targeted Autologous Cell Therapy

Coalition to Cure Calpain 3 (C3) is pleased to announce the publication of important research undertaken by Dr. Rita Perlingeiro, Professor of Medicine, University of Minnesota, and colleagues. The paper, titled “Gene Correction of LGMD2A Specific iPSCs for the Development of Targeted Autologous

Together we are STRONGER: 5th Annual LGMD Awareness Day is Coming Up!

The 5th annual Limb Girdle Muscular Dystrophy Awareness Day is coming up on September 30, 2019. Help C3 raise awareness of LGMD in your community and through social media. It’s time to: 1. Start planning to wear Lime Green on

Individuals with LGMD are sought for clinical trial evaluating the safety and efficacy of oral weekly glucocorticoid steroids

A clinical trial is being initiated at Northwestern University in Chicago, Illinois. The aim of the study is to test the safety and efficacy of once weekly dosing of oral prednisone, a glucocorticoid steroid. Both ambulatory and nonambulatory patients

Dr. Stefanie Müthel Awarded First Early Career Investigator Travel Grant

Coalition to Cure Calpain 3 (C3) is pleased to announce that Dr. Stefanie Müthel was awarded a Travel Grant for the presentation of her research at the Biology of Calpains in Health and Disease Conference in Pacific Grove, California, from

Patients Sought for C3-funded Clinical Endpoints Study

Coalition to Cure Calpain 3 (C3) is pleased to announce that a research grant has been awarded to Dr. Nicholas Johnson, Associate Professor & Vice Chair of Research, Virginia Commonwealth University. The project is titled “Defining Clinical Endpoints in LGMD.”

C3 Hosts Gene Therapy for LGMD2A Workshop

Coalition to Cure Calpain 3 (C3) is committed to treating and ultimately curing limb-girdle muscular dystrophy, type 2A (LGMD2A), a form of calpainopathy. C3’s mission is to fund therapeutically relevant research and clinical trials as we educate the global community about

May 20 is Clinical Trials Awareness Day

It is CLINICAL TRIALS AWARENESS day… C3 often gets asks, are there any clinical trials underway for LGMD2A (a form of calpainopathy)? Yes! One form of clinical trial, called a natural history study, is currently underway. This type of study